Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.
source https://finance.yahoo.com/news/inovio-ends-enrollment-anal-dysplasia-211409945.html?.tsrc=rss
Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.
source https://finance.yahoo.com/news/inovio-ends-enrollment-anal-dysplasia-211409945.html?.tsrc=rss
blaineonline.finance.blog 